Stimulation on Demand: Closing the Loop on Deep Brain Stimulation  by Santos, Fernando J. et al.
Neuron
PreviewsStimulation on Demand: Closing
the Loop on Deep Brain StimulationFernando J. Santos,1 Rui M. Costa,1,* and Fatuel Tecuapetla1,*
1Champalimaud Neuroscience Programme at Instituto Gulbenkian de Cieˆncia, Rua da Quinta Grande, 2780-901 Oeiras, Portugal
*Correspondence: ruicosta@fchampalimaud.org (R.M.C.), fatuel.tecuapetla@neuro.fchampalimaud.org (F.T.)
DOI 10.1016/j.neuron.2011.10.004
High-frequency open-loop deep brain stimulation (DBS) has been used to alleviate Parkinson’s symptoms for
almost 20 years. In this issue of Neuron, Rosin et al. present a closed-loop real-time approach that improves
DBS and shines light on the etiology of motor symptoms in Parkinson’s disease.In Parkinson’s disease (PD), depletion of
dopamine after degeneration of dopami-
nergic neurons (Carlsson, 1972; Horny-
kiewicz, 1966), mostly in substantia nigra
pars compacta, leads to a variety of
motor symptoms including bradykinesia,
tremor, and rigidity. This dopamine deple-
tion has consequences for the activity
of cortico-basal ganglia circuits. A well-
accepted view postulates that lack of
dopamine in PD leads to increased
activity of indirect pathway neurons (stria-
topallidal, which mainly express D2-type
dopamine receptors) and decreased ac-
tivity of direct pathway neurons (striato-
nigral, which mostly express D1-type
dopamine receptors) (Albin et al., 1989),
ultimately leading to increased activity
in globus pallidus internus (GPi) and to
overinhibition of thalamus and cortex.
Another view proposes that dopamine
depletion leads to abnormal network os-
cillations in basal ganglia, which produce
excessive synchrony (Brown, 2003; Gold-
berg et al., 2004).
Currently, the first approach to alleviate
PD symptoms is the administration of
drugs to restore dopamine, most notably
L-Dopa. However, L-Dopa typically be-
comes less effective with time. Another
successful approach is the use of high
frequency deep brain stimulation (DBS)
in basal ganglia nuclei, mainly in the sub-
thalamic nucleus (STN), the GPi, or the
thalamus (Wichmann and Delong, 2006).
The first reports of the use of DBS to
treat -PD patients date to 1994 (Limousin
etal., 1995). The paradigms currently used
for DBS are based on continuous stimu-
lation, or ‘‘open-loop DBS,’’ because the
stimulation pattern and intensity are set
by an external stimulator and adjusted
manually. Although the mechanisms bywhich DBS stimulation works are still
under debate, this strategy has helped
more than 55,000 people suffering not
only from PD but also from other motor
disorders (Miller, 2009).
In this issue of Neuron, Rosin, Berg-
man, and colleagues (Rosin et al., 2011)
develop a new strategy for DBS in the
basal ganglia using a closed-loop para-
digm, in which the activity of neurons in
a reference brain area is used as the
trigger for stimulating the target area
(Figure 1). Using primates treated with
MPTP, which causes dopaminergic neu-
ron degeneration and PD-like symptoms
(Burns et al., 1983), the authors compare
the effects of different closed-loop para-
digms and standard continuous or open-
loop DBS protocols in akinesia and pal-
lidal firing properties. These comparisons
show that closed-loop paradigms with
real-time adaptive stimulation have less
undesirable side effects and more clinical
benefits than standard paradigms.
One of the great advantages of closed-
loop strategies relatively to standard
DBS protocols is the possibility for auto-
matic and constant adaptation to the
dynamics of the disease in each patient
over time. Currently, PD patients that
undergo DBS treatments need to have
periodic medical assistance by a trained
clinician in order to have the stimulation
parameters adjusted to the development
of the disease, and parameters remain
unchanged between adjustments. In this
novel closed-loop DBS paradigm, neu-
ronal spikes recorded in the primary
motor cortex (M1) were used as an online
trigger for stimulation (trains or single
spikes) delivered to the GPi. This para-
digm yielded a marked reduction in
akinesia in all four limbs, but most notablyNeuron 72in the contralateral arm to the stimulation
site, as measured by accelerometers.
Importantly, this adaptive closed-loop
DBS successfully triggered a reduction
of pallidal firing rate and a decrease of
oscillatory activity in GPi (Rosin et al.,
2011).
The use of closed-loop DBS with motor
cortex as the reference structure for trig-
gering pallidal stimulation led to a reduc-
tion of stimulation frequency and also
to an increase in the variability of the
interstimulus interval when compared
with standard high frequency stimulation.
Could the improvements observed simply
reflect the fact that the stimulation pattern
was of lower frequency and more irreg-
ular? In order to demonstrate that the
observed effects were due to the adaptive
closed-loop nature of the stimulation, the
authors performed two experiments. In
one they applied an open-loop stimulation
at low frequency (10 Hz versus standard
DBS at 130 Hz). In another, they applied
a stimulation pattern based on previous
recordings from M1, with the same vari-
ability as the online adaptive stimulation
pattern, but unrelated to the ongoing
activity at the moment of the stimulation.
In both cases no relevant improvements
in behavior or neuronal modulation were
observed, strengthening the conclusion
that it was not the statistics of the stimula-
tion pattern that promoted the behavioral
improvements in closed-loop DBS, but
rather the fact that the stimulation pattern
reflected ongoing activity.
This study offers important insights into
how DBS works. Previous studies sug-
gested that there is increased neural ac-
tivity in the STN ofMPTP-treated primates
(Crossman et al., 1985). Accordingly, le-
sioning the STN in the MPTP primate, October 20, 2011 ª2011 Elsevier Inc. 197
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Figure 1. Illustration of an Open-Loop and an Adaptive Closed-Loop Deep Brain Stimulation
(DBS) Paradigm
(A) Standard ‘‘open-loop’’ high-frequency (130 Hz) DBS consists of continuous stimulation of a target
structure (i.e., internal segment of the globus pallidum, GPi) through an implanted electrode.
(B) Adaptive ‘‘closed-loop’’ DBS consists of using the online activity of a reference structure (i.e., primary
motor cortex, M1) as a trigger for stimulation of the target structure (i.e., GPi) after a certain delay (i.e.,
80 ms). This results in a lower frequency and more irregular pattern of stimulation and promotes a
substantial reduction of Parkinsonian akinesia compared with standard ‘‘open-loop’’ DBS protocols, by
adapting the stimulation to the dynamics of cortico-basal ganglia networks.
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toms (Bergman et al., 1990). Since both
electrical stimulation of STN and STN
lesions produced amelioration of PD
symptoms, it was hypothesized that DBS
leads to decreased activity in STN or
decreased transmission from STN to
GPi, therefore leading to reduced activity
in GPi. Another suggestion has been that
both STN lesions and DBS would disrupt
the pathological oscillations observed in
PD, leading to an improvement in motor
symptoms; this view is supported by
recent studies which suggest that DBS
does not work by inhibiting STN neurons
(Bar-Gad et al., 2004; Carlson et al.,
2010;Gradinaru et al., 2009). Interestingly,
Rosin and colleagues uncovered that
the application of a closed-loop protocol
in which GPi activity triggered GPi
stimulation resulted in a reduction in
pallidal discharge rate with no change in
GPi oscillatory activity, and even in an
increase in oscillatory activity in motor
cortex (Rosin et al., 2011). In this situation,
not only did akinesia in MPTP-treated
primates not improve, but it got worse,
suggesting that the ameliorating effects
of DBS do not stem from reducing GPi
activity, but likely from disrupting patho-
logical oscillatory activity in the basal
ganglia.
These experiments also give invaluable
insight into the mechanisms underlying198 Neuron 72, October 20, 2011 ª2011 Elsethe motor symptoms in PD. The fact
that a decrease in GPi discharge rates
with an increase in cortical oscillations
resulted in an aggravation of akinesia,
suggests that motor symptoms in PD are
related to changes in oscillatory activity
in cortico-basal ganglia circuits and not
simply caused by an increase in the firing
rate of GPi as a result of an imbalance
between the activity of the direct and
indirect pathways.
Although this study is very promising, it
opens several questions for future exper-
iments. Which are the optimal parameters
for closed-loop DBS? Can different struc-
tures be used as reference or targets?
What kind of signals can be used as
triggers in order to allow for long-term
stability? In this paradigm a single spike
in the reference structure would trigger
stimulation, but it may be difficult to
record M1 spikes during long periods of
time. The use of signals that could be
recorded reliably for longer periods of
time, like local field potential oscillations,
could aid the long-term implementation
of these close-loop strategies. It also
remains to be determined how robust
and stable the ameliorating effects would
be after long-term exposure to such a
treatment.
Furthermore, the approach taken by
the authors can be the starting point to
apply closed-loop DBS strategies to othervier Inc.disorders, like neuropsychiatric disor-
ders. It is becoming increasingly apparent
that several diseases like schizophrenia,
epilepsy, obsessive-compulsive disor-
ders, Tourette syndrome, and depression
could be treated using brain stimulation
(Miller, 2009; Wichmann and Delong,
2006), and the real-time adaptive stimu-
lation paradigm presented here could
also offer significant advantages in the
treatment of the associated symptoms.
Hopefully, future studies in animal mod-
els will help disentangle not only how
these pathologies emerge, but also define
the best strategies to improve clinical
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